PIRFENIDONE

EUEMA:by INNUSDailyMed:Pirfenidone AU:B3 L04AX05(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 5-Methyl-1-phenylpyridin-2-one 53179-13-8 40632 DB04951 37115 D7NLD2JX7U D01583Y CHEBI:32016Y ChEMBL1256391N DTXSID4045183 Interactive image CC1=CN(C(=O)C​‍​​​​​‍​‍‍‍‍​‍‍=C1)C2=CC=CC=C2 InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3Key:ISWRGOKTTBVCFA-UHFFFAOYSA-N Pirfenidone, sold under the brand nameEsbrietamong others, is amedicationused for the treatment ofidiopathic pulmonary fibrosis. It works by reducing lung fibrosis through downregulation of the production ofgrowth factorsandprocollagensI and II. It was first approved in Japan for the treatment of people with idiopathic pulmonary fibrosis after clinical trials in 2008. It was approved for use in the European Union in 2011,in Canada in 2012,and in the United States in October 2014. It is available as ageneric medication.